Novavax (NVAX) Tops Q1 EPS by $3.36
Novavax (NASDAQ: NVAX) reported Q1 EPS of $2.93, $3.36 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $667 million versus the consensus estimate of $251.8 million.
GUIDANCE:
Novavax sees FY2025 revenue of $975-1025 million.
Financial Framework
Reiterates Full Year 2025 Financial Guidance
Novavax is reiterating Full Year 2025 Financial Guidance for combined R&D and SG&A expenses and currently expects to achieve the following results:
$ in millions | Full Year 2025 (as of | Full Year 2025 (as of |
Combined R&D and SG&A Expenses |
Raises Full Year 2025 Revenue Framework
Novavax transitioned lead commercial responsibility of Nuvaxovid beginning with the 2025-2026 vaccination season to Sanofi for select markets. Since Novavax is reliant on Sanofi's sales forecasts for certain revenue components, these are not included in the Full Year 2025 Revenue Framework. For 2025, Novavax currently expects to achieve Adjusted Total Revenue1 of between
$ in millions | Full Year 2025 (as of | Full Year 2025 (as of |
Sanofi Supply Sales | No guidance | No guidance |
Sanofi Royalties | No guidance | No guidance |
Sanofi Influenza-COVID-19 Combination and Matrix-M Milestones | No guidance | No guidance |
Nuvaxovid Product Sales2 | $610 | No guidance |
Adjusted Supply Sales3 | ||
Adjusted Licensing, Royalties and Other Revenue 4,5,6,7 | ||
Adjusted Total Revenue1 |
For earnings history and earnings-related data on Novavax (NVAX) click here.